In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.
about
Melanized fungi in human diseaseIsavuconazole in the treatment of invasive aspergillosis and mucormycosis infectionsIsavuconazole: A New Broad-Spectrum Triazole Antifungal AgentUse of amplified fragment length polymorphism to identify 42 Cladophialophora strains related to cerebral phaeohyphomycosis with in vitro antifungal susceptibility.In vitro antifungal activity of isavuconazole against Madurella mycetomatisIsavuconazole: A New Option for the Management of Invasive Fungal Infections.Quantitative Microplate-Based Growth Assay for Determination of Antifungal Susceptibility of Histoplasma capsulatum Yeasts.Preliminary laboratory report of fungal infections associated with contaminated methylprednisolone injections.New generation azole antifungals in clinical investigation.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Use of Antifungal Combination Therapy: Agents, Order, and Timing.Use of posaconazole in the treatment of invasive fungal infections.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Profile of isavuconazole and its potential in the treatment of severe invasive fungal infectionsPathogenesis and host defence against Mucorales: the role of cytokines and interaction with antifungal drugs.Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Isavuconazole: a new extended spectrum triazole for invasive mold diseases.Clinical Manifestations and Treatment of Blastomycosis.Terpinen-4-ol, tyrosol, and β-lapachone as potential antifungals against dimorphic fungi.In vitro antifungal susceptibility profile and correlation of mycelial and yeast forms of molecularly characterized Histoplasma capsulatum strains from India.Newer antifungal agents.In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries.In vitro activity of isavuconazole against fluconazole-resistant isolates of Histoplasma capsulatum.Histoplasmosis and Blastomycosis in Solid Organ Transplant Recipients.In vitro antifungal activity of miltefosine and levamisole: their impact on ergosterol biosynthesis and cell permeability of dimorphic fungi.Potent Activity of Luliconazole, Lanoconazole and Eight Comparators against Molecularly Characterized Fusarium species.Success of posaconazole therapy in a heart transplanted patient with Alternaria infectoria cutaneous infection.Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
P2860
Q24633163-A9F8E24C-F27D-413E-A805-FA87321563EAQ26744049-80C598DD-FBF9-4180-92AF-D80A55F3FFA7Q28082019-B87B4677-BB89-463F-B431-6FD54A8CBA37Q33565219-585F9B18-005F-4552-8E47-0DFD695D4BF0Q34298778-70F62D86-E036-4ED2-88F3-75DE436B04F7Q34474946-B13B5A0F-1759-4B01-B666-D35096B6FDBBQ36066802-D436947D-4198-49DA-A71A-6AFC73CE1E74Q37036276-0D595ECE-C320-49E4-A1E8-38B165BA3518Q37579222-3542B9C3-5951-4523-B2EF-4994DB5A1EE5Q37608276-23CD2973-5C90-45C1-BF49-481C81F98F43Q37767359-3FCC20E2-08CE-4ECE-88F7-ED02B44B6B7DQ37810083-BDA3E8BB-0DDB-4FBC-A60E-C1CB80AD3383Q37918556-7710AB49-5C2D-4AB2-94AB-C2FD6D7B6AD5Q38159688-3FED81F2-1819-4865-B59D-EE135C90D9B0Q38245046-F703DA41-237D-4CC3-9D6A-74C354F18DB8Q38285488-0938C793-4A0B-4594-A9FE-BD16982035C4Q38534865-776A6751-23D2-4345-9387-4E826724A21FQ38939506-0B0D3A21-7299-4AB9-A846-17151A79B6BAQ39003715-2D51957B-5718-4AFC-B6E8-04F3B45A5759Q40098273-4BF31B9B-3546-4410-96FA-4B3D6A26E0FCQ41342100-2EE1B93A-83ED-41EC-A373-23E30F0FECAAQ42109717-E39311C8-80F9-42DD-8442-A50B6F923C26Q44855715-777D2563-0D2C-4684-9161-4A506DD189C6Q45238820-21468E66-C6F1-42B3-8AB6-5D5E045B31D4Q47290283-667BB2ED-CFB4-4B53-8F43-3AB655A5EE4CQ47643761-10CB72D2-E97D-4661-B719-8398C5581DC7Q50537029-59F33213-FC54-4B8E-8BF7-1E5DF801974DQ51149218-95928B51-EA86-40F1-9BA8-220ACC19E74FQ51379568-159B59BC-F296-4168-91A3-E1293FEA9FDFQ53779321-322E49B4-A092-4A0A-9939-BA4077AA31F7Q54214603-D6EB773A-B332-488F-B1EA-DA3DC2671687
P2860
In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
In vitro activities of isavuco ...... lamentous and dimorphic fungi.
@en
In vitro activities of isavuco ...... lamentous and dimorphic fungi.
@nl
type
label
In vitro activities of isavuco ...... lamentous and dimorphic fungi.
@en
In vitro activities of isavuco ...... lamentous and dimorphic fungi.
@nl
prefLabel
In vitro activities of isavuco ...... lamentous and dimorphic fungi.
@en
In vitro activities of isavuco ...... lamentous and dimorphic fungi.
@nl
P2860
P1433
P1476
In vitro activities of isavuco ...... lamentous and dimorphic fungi.
@en
P2093
Gloria M González
P2860
P356
10.1080/13693780802562969
P577
2008-12-18T00:00:00Z